| Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
| 2018-04-23 |
Innovation Pharmaceuticals (USA - MA) Evonik (Germany) |
brilacidin |
|
production |
Technology - Services - Cancer - Oncology |
Production agreement |
| 2018-04-23 |
Lysogene (France) |
member of the board of directors |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
| 2018-04-17 |
Akcea Therapeutics (USA - CA), a subsidiary of Ionis Pharmaceuticals (USA - CA) |
president - member of the board of directors |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
| 2018-04-16 |
RoslinCT (UK) Northern Alliance Advanced Therapies Treatment Centre (NAATTC) (UK) |
|
|
collaboration |
|
Collaboration agreement |
| 2018-04-13 |
Takeda Pharmaceutical (Japan) |
Shonan Health Innovation Park |
|
opening of new premises |
|
Opening of new premises |
| 2018-04-12 |
GSK (UK) Orchard Therapeutics (UK) Molmed (Italy) |
approved and investigational rare disease gene therapies including Strimvelis® |
adenosine deaminase severe combined immunodeficiency (ADA-SCID), metachromatic leukodystrophy (MLD), Wiskott Aldrich syndrome (WAS) , beta thalassaemia, mucopolysaccharidosis type 1 (MPS1 or Hurler syndrome), chronic granulomatous disease (CGD), globoid cell leukodystrophy (GLD) |
pipeline acquisition |
Rare diseases - Genetic diseases |
Pipeline acquisition |
| 2018-04-12 |
BioInvent (Sweden) |
chief executive officer |
|
nomination |
Cancer - Oncology |
Nomination |
| 2018-04-11 |
Arbutus Biopharma (Canada) Roivant Sciences (USA) Genevant Sciences (USA - MA) |
- RNA-based therapeutics enabled by Arbutus’ proprietary lipid nanoparticle (LNP) and ligand conjugate delivery technologies.
|
|
- development
- joint-venture
|
Rare diseases - Genetic diseases |
Joint-venture agreement |
| 2018-04-10 |
Wave LIfe Sciences (USA - MA) Deep Genomics (Canada) |
|
|
collaboration |
Rare diseases - Genetic diseases - Neuromuscular diseases |
Collaboration agreement |
| 2018-04-09 |
Pfizer (USA - NY) Allogene Therapeutics (USA - CA) |
allogeneic chimeric antigen receptor T cell (CAR T) therapy |
|
collaboration |
Cancer - Oncology |
Collaboration agreement |
| 2018-04-04 |
Avrobio (USA - MA) |
member of the board of directors |
|
nomination |
Cancer - Oncology - Rare diseases - Genetic diseases - Lysosomal diseases |
Nomination |
| 2018-04-04 |
Iontas (UK) IGEM Therapeutics (UK) |
IgE antibodies against two undisclosed targets |
|
collaboration |
Cancer - Oncology |
Collaboration agreement |
| 2018-04-03 |
BeiGene (China) |
member of the board of directors |
|
nomation |
Cancer - Oncology |
Nomination |
| 2018-04-03 |
Tmunity Therapeutics (USA - PA) |
chief technology officer |
|
nomination |
Cancer - Oncology |
Nomination |
| 2018-03-28 |
Celgene (USA - NJ) Bluebird bio (USA - MA) |
product candidates targeting B-cell maturation antigen (BCMA) including bb2121 and bb21217 |
multiple myeloma |
collaboration - development |
Cancer - Oncology |
Development agreement |
| 2018-03-27 |
Nabriva Therapeutics (Austria) Roivant Sciences (USA) |
lefamulin |
|
development - commercialisation |
Infectious diseases |
Development agreement |
| 2018-03-26 |
Nanomedsyn (France) Shire (UK - USA) |
- enzyme replacement therapy using AMFA (recombinant human acid alpha-glucosidase conjugated with mannose-6-phosphate analogues)
|
undisclosed lysosomal disease |
R&D - research |
Rare diseases - Genetic diseases |
Research agreement |
| 2018-03-21 |
Alnylam Pharmaceuticals (USA - MA) Regeneron Pharmaceuticals (USA - NY) |
RNAi therapeutics |
NASH (non-alcoholic steatohepatitis) and potentially other related diseases |
R&D - research |
Hepatic diseases - Liver diseases |
Research agreement |
| 2018-03-19 |
Five Prime Therapeutics (USA - CA) UCB (Belgium) |
undisclosed drug target for inflammatory diseases |
inflammatory diseases |
licensing |
Inflammatory diseases |
Licensing agreement |
| 2018-03-13 |
Avexis (USA - IL) Genethon (France) |
- AVXS-101 (adeno-associated virus serotype 9 expressing the human Survival Motor Neuron gene) - AAV9-SMN product and route of administration
|
spinal muscular atrophy |
licensing |
Rare diseases - Genetic diseases - Neuromuscular diseases |
Licensing agreement |
